At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
Capecitabine +1 moredrug
Likely dose
Capecitabine 1000 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Of Sunitinib Malate In Combination With Capecitabine In Patients With Advanced Or Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Capecitabine and Sunitinib for Advanced/Metastatic Breast Cancer. Completed, enrolled 63 participants across 17 sites.
Detailed Summary
To evaluate efficacy, safety and pharmacokinetics of sunitinib plus Capecitabine in Japanese patients with advanced/metastatic breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced/Metastatic Breast Cancer
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedApr 2008
Primary CompletionDec 2009
Study CompletionMay 2012
TodayJul 2026
First PostedApr 21, 2008
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2009
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.2 years ago
Interventions
Capecitabinedrug
Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
Sunitinibdrug
Sunitinib 37.5 mg daily, continuous dosing